Anti-IRS1 (phospho Y632) 抗体 [EPR259(2)]

• WB

Unknown

Western blot - Anti-IRS1 (phospho Y632) antibody [EPR259(2)] (AB109543)

All lanes:

Western blot - Anti-IRS1 (phospho Y632) antibody [EPR259(2)] (ab109543) at 1/1000 dilution

Lane 1:

293T cell lysate, untreated at 10 µg

Lane 2:

293T cell lysate treated with Alkaline Phosphatase at 10 µg

Secondary

All lanes:

HRP-labelled goat anti-rabbit at 1/2000 dilution

Predicted band size: 131 kDa

false

• WB

CiteAb

Western blot - Anti-IRS1 (phospho Y632) antibody [EPR259(2)] (AB109543)

IRS1 (phospho Y632) western blot using anti-IRS1 (phospho Y632) antibody [EPR259(2)] ab109543. Publication image and figure legend from Song, Q., Sun, X., et al., 2017, Oncotarget, PubMed 28002807.

ab109543 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab109543 please see the product overview.

The RTK/IRS1-mediated reactivation of AKT was responsible for the insufficient inhibition of the cell growth by the AKTi(A) HCT-116 cells were pretreated with AKTi for 46 hr, and then treated with AKTi or RTKis (LOJ) for 2 hr. The whole cell lysates were processed for western blot and probed with indicated antibodies. Relative AKT phosphorylation levels were quantified to DMSO treatment, and illustrated as numbers below the blots. (B) SW1116 cells were treated with AKTi at various concentrations for 1 hr and 24 hr. The whole cell lysates were processed for western blot and probed with indicated antibodies. (C) Phospho-RTK arrays of SW1116 cells, which were treated with DMSO (NC) or MEKi for 24 hr. Positive dots were numbered and illustrated below the arrays. (D) SW1116 cells which were pretreated with 0.25 μM AKTi for 24 hr and then treated with 10 μM LY294002 (PI3Ki), 2.5 μM GSK2334470 (PDKi), or 1 μM triciribine (PIP3-AKT binding inhibitor) for 1 hr. The whole cell lysates were processed for western blot and probed with indicated antibodies. (E) LS174T, LOVO and HCT-116 cells were treated with single RTKi or the specific RTKis with or without AKTi for 24 hr. The whole cell lysates were processed for western blot and probed with indicated antibodies. IRS1 phosphorylation (Tyr895) was quantified and normalized to DMSO treatment (bottom panel). The drug concentrations were as follows : AKTi : 0.25 μM; LAP (L) : 0.5 μM; OSI (O) : 0.5 μM; JNJ (J) : 0.05 μM.

false